Nurlan Mammadzada

İç hastalıkları ve Tıbbi Onkoloji Uzmanı

[Elshad Hasanov, MD, PhD @HasanovLab]

Proud to see our PhD student, @MostafaIHA, present his work on the single-cell and spatial landscape of RCC brain metastases @OSUCCC_James @OhioStatePIIO @Pelotonia.

Using single-nucleus RNA-seq, spatial transcriptomics, and computational biology, his research explores mechanisms of immune dysfunction and therapeutic resistance in CNS metastases.

Excited to see this work advance our understanding of brain metastasis biology and precision oncology.

#KidneyCancer #BrainMetastases #SingleCell #SpatialTranscriptomics #PrecisionOncology #HasanovLab #OSUCCC #CodeToClinic

[Emre Yekedüz @yekeduz_emre]

Congratulations to @oncoxman on a great poster at #ASCO26 !

👉The prognostic significance of teratoma components in germ cell tumor patients undergoing HDCT-ASCT.

@DrYukselUrun @onkolojidernegi @OncoAlert @ONCOassist @urotoday #cancer #oncology

[Nurlan Mammadzada @docnurlan]

What an amazing experience connecting with @AndreaNecchi in our mentor-mentee program! 🌟 Your perspective on the future of precision oncology has expanded my vision in ways I didn’t expect. Thank you for generously sharing your knowledge and opening new doors.

[Elshad Hasanov, MD, PhD @HasanovLab]

Excited to share our upcoming presentations at #ASCO2026 from the @HasanovLab @OhioStatePIIO and collaborators.
This year, our team will present 12 studies spanning:
https://t.co/jlGQZKe0vq
🤖 AI/ML precision oncology
🧠 RCC brain metastasis biology
🧫 Spatial & single-cell transcriptomics
🌎 Real-world outcomes research with ML models
💻 In silico clinical trial modeling
These projects reflect our 💻 #CodetoClinic 👩‍⚕️👨‍⚕️translational framework, integrating computational oncology, multi-omics, and clinical research to advance precision cancer care.
Grateful to our incredible trainees, collaborators, patients, and mentors who made this work possible. https://t.co/8SlON6F4d0

@OSUCCC_James @ASCOPost @ASCO @KidneyCancer @kidneycan @urotoday @OncoAlert @oncodaily @OncLive

#KidneyCancer #BrainMetastases #PrecisionOncology #AIinOncology #SpatialBiology #SingleCell #TranslationalResearch

[Dr Rishabh Jain @DrRishabhOnco]

🚨 THE 15 MOST IMPORTANT TRIALS OF #ASCO26

May 29 - June 2 | Chicago
Which trial are you watching most closely?

🌟 PLENARY GAME-CHANGERS

1️⃣ PROTEUS
Perioperative apalutamide + ADT in high-risk localized prostate cancer

2️⃣ LIBRETTO-432
Adjuvant selpercatinib in RET+ NSCLC

3️⃣ HARMONi-6
Ivonescimab + chemo vs tislelizumab + chemo in squamous NSCLC

4️⃣ RASolute 302
Daraxonrasib (RMC-6236) in metastatic pancreatic cancer

5️⃣ SARC041
Abemaciclib in dedifferentiated liposarcoma

⚡ FRONTLINE & PERIOPERATIVE SHIFTS

6️⃣ KEYNOTE-B15 / EV-304
EV + pembrolizumab vs chemo in MIBC

7️⃣ LITESPARK-022
Pembrolizumab + belzutifan in adjuvant ccRCC

8️⃣ AMBITION
Paclitaxel/bevacizumab ± atezolizumab in HR+ breast cancer

9️⃣ NeoADAURA
Neoadjuvant osimertinib in EGFR+ NSCLC

🔟 A-DREAM
ADT interruption strategies in mCSPC

🧬 PRECISION, ADCs & NEXT-GEN IMMUNOLOGY

1️⃣1️⃣ DESTINY-Breast06
T-DXd expands into HER2-ultralow disease

1️⃣2️⃣ CROWN (7-year update)
Lorlatinib durability in ALK+ NSCLC

1️⃣3️⃣ DeLLphi-312
Tarlatamab in frontline SCLC

1️⃣4️⃣ COMMIT
Atezolizumab + FOLFOX/Bev in MSI-H mCRC

1️⃣5️⃣ IMvigor011
ctDNA-guided adjuvant atezolizumab in bladder cancer

#OncoTwitter #MedTwitter #ASCO26 #CancerResearch @OncoAlert @ASCO @JCOPO_ASCO @OncBrothers

[Mushtaq Bilal, PhD @MushtaqBilalPhD]

https://t.co/ERrKQgLB3w

[Hong Jae Chon @hongjaechon]

🎯 Paradigm shift in unresectable HCC treatment!
A new editorial by Prof. Masatoshi Kudo @KudoM_Kindai highlights why we MUST rethink stopping treatment at the first RECIST-defined PD (published in Liver Cancer @ResearchKarger).
👉 Continuous sequential Triple Therapy (ICI + Anti-VEGF/TKI + On-demand TACE) is a game-changer.
👉 Don't stop at first RECIST-defined PD! Continue systemic therapy & repeat TACE until "unTACEable progression" occurs.
👉 This strategy maximizes Deep Response (DpR) and opens the door to curative conversion surgery (Cancer-free & Drug-free status!).
@ILCAnews @myESMO @ASCO @EASLnews
Full text: https://t.co/qEDJp5vkkU
#HCC #LiverCancer #Oncology #TripleTherapy #Immunotherapy #TACE

[Antonio Ocejo @ja_ocejo]

#ASCO26 Trainee & Early Career Lounge mentoring links:

🔵Fri 5/29: sign up https://t.co/jwGqob4wGQ
🔵Sat 5/30: sign up https://t.co/yUZmJxM9r3
🔵Sun 5/31: sign up https://t.co/nptpCPpBrT
🔵Mon 6/1: sign up https://t.co/uOQ1Oud4lV

[Dr Rupam Manna MD @DrRupamOncology]

Neuroendocrine Tumors (NETs) — one-page mastery 🧬

From Ki-67 grading → classification → targeted therapy, this is the framework you need for both exams & clinics.

🔑 Remember:
• Grade drives treatment
• SSA = first-line (low-grade)
• PRRT = game changer
• NEC → treat like SCLC

#MedicalOncology #NETs #Oncology #DrNB #DMOncology #OncoTwitter #MedEd #CancerEducation #PRRT #ExamPrep

[Dr Rishabh Jain @DrRishabhOnco]

🔥 ADC + Immunotherapy in TNBC?
#ESMOBreast26

Early data from 426RO trial shows a striking signal in 1L mTNBC 👇

🧪 Trial: Phase I/II (n=30)
👥 Population: 1L advanced/metastatic TNBC

💊 Regimen
👉 Pumitamig (PD-L1 × VEGF-A bispecific)
➕
👉 DB-1305/BNT325 (TROP2 ADC)

🎯 Results
✨ ORR: 75.9% (confirmed)
✨ DCR: 96.6%
✨ Median follow-up: 5.5 months

⚠️ Safety
▪ Grade ≥3 AEs: 43%
▪ Stomatitis (G≥3): 16.7%
▪ Dose mods: ~30%

💡 Takeaway
👉 Powerful efficacy signal
👉 ADC + IO synergy looks real
👉 But early, small, single-arm

🚨 Not practice-changing yet

#ESMOBreast26 #OncoTwitter #MedTwitter #BreastCancer #TNBC @OncoAlert @myesmo @esmo_open @asco @Larvol

[gilberto lopes @GlopesMd]

@asco #asco26 is four weeks away. Looking forward to seeing everyone in Chicago.

Eagerly awaited: Plenary Session trials

PROTEUS - Perioperative apalutamide + ADT vs placebo + ADT with radical prostatectomy in high-risk localized / locally advanced prostate cancer

SARC041 - Abemaciclib vs placebo in advanced dedifferentiated liposarcoma

LIBRETTO-432 - Adjuvant selpercatinib vs placebo in stage IB–IIIA RET fusion–positive NSCLC

HARMONi-6 - Ivonescimab + chemotherapy vs tislelizumab + chemotherapy in previously untreated advanced squamous NSCLC (overall survival results)

RASolute 302 - Daraxonrasib (RAS(ON) multi-selective inhibitor) vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma

@OncoAlert @OncBrothers @uicc @IASLC @COlazagasti @Latinamd @Jani_Chinmay @JackWestMD

[Paolo Tarantino @PTarantinoMD]

It’s that time of the year again! #ESMOBreast26 is only a few days away, and promises to bring new important data in breast oncology. This year’s key themes: tailoring therapy for HER2+ eBC, prospective data with ADC sequencing, use of MRD to guide treatment. See you in Berlin!

[Dr Rishabh Jain @DrRishabhOnco]

🚨 FDA’s take on SERENA-6 is basically this:
“Nice data… but are we helping patients?”

Let’s break it down 👇

🧠 Problem 1: Wrong question

Trial asks:
👉 Switch early vs don’t switch

But real-world question is:
👉 Switch early vs switch later
FDA:
❌ “You didn’t answer the real question.”

⏱️ Problem 2: The PFS illusion

PFS looks great (16 vs 9.2 months)

But… it starts from:
👉 ESR1 mutation detection (not progression)

FDA:
❓ “What does this PFS even mean clinically?”

🧬 Problem 3: Biology mismatch

We assume: ESR1 mutation = resistance

FDA says:
👉 Not so fast

Patients may still benefit from AI + CDK4/6i
even AFTER mutation appears

👉 Early switch = stopping a working drug

🔁 Problem 4: No second chance

Control arm never got camizestrant later ❌

So we don’t know:
👉 Early vs delayed use

FDA:
❌ “This comparison is incomplete”

📉 Problem 5: Where is survival benefit?

OS = immature
Final data → years away

FDA:
👉 “Without OS, paradigm shift is risky”

⚠️ Problem 6: Not risk-free

QT prolongation
Bradycardia
Rare TdP

👉 Not a harmless switch

🎯 FDA’s real message:

“Just because we can act early…
doesn’t mean we should.”

🔖 Save this - this is how regulators think

📖 Full FDA briefing in comment ⬇️

#OncoTwitter #MedTwitter #BreastCancer #ESMOBreast26
@OncoAlert @myesmo @esmo_open @asco @OncBrothers

[Uğur Özkerim @UOzkerim]

🚨 New ALK inhibitor on the horizon!

Deulorlatinib (TGRX-326) shows promising activity in ALK+ NSCLC after 2nd-gen TKI failure (DRAGON phase II)

🎯 ORR: 43.7%
🧠 CNS ORR: 55.8%
🧬 G1202R: ORR 62.5%

A compelling option emerging for resistant ALK+ disease.
@OncoAlert @MedwatchKate @OncoReporte @ManuelDomine @MedicalwatchHQ

[Nicholas Hornstein @GIMedOnc]

#ASCO26 is coming up!
With abstracts released I put together a top 10 (ok, top 12) GI abstracts I'm excited for.
Some things might fall off (or be added) pending full abstract text, but these are what I'm watching for and might be practice changing or scientifically interesting.

@ASCO @Onco_Nexus @OncoAlert @TheGutOncLab

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

🫁 My pick of 10 lung cancer trials that will define practice at #ASCO2026 @ASCO

From sunvozertinib in exon20ins to 7-year CROWN data to TRITON in STK11/KEAP1/KRAS; the data is coming.

Which one are you watching?

@OncoAlert @LungCancerRx @oncodaily @EGFRResisters @KRASKickers

[Teoman Yanmaz @mtymtyyanmaz]

2000’lerin başında Onkolojiye başladığımda met khd akciğer kanseri hastalarının OS ≈ 8-10 aydı. 2010 gibi 1-2 çalışmada sağlanan 1 yıl OS büyük haber oldu. Şimdi en kötü tipinde 2. basamakta PFS>11 ay. En çok ölüme neden olan kanseri, insanlık altetmek üzere, umutluyuz 🤗

[Stephen V Liu, MD @StephenVLiu]

Dr. @riess_md at #AACR26 updates RMC-9805 (zoldonrasib) in KRAS G12D NSCLC. Very impressive. G12D is a particular need in lung cancer as many patients have no smoking history and do not fare as well with immunotherapy. Zoldonrasib is a mutant selective, RAS(ON) inhibitor.

[Nicholas Hornstein @GIMedOnc]

RevMed absolutely stole the show at AACR with their Pan-RAS and G12D inhibitors.

First line panc, second line NSCLC, even in early trials this is extremely compelling data.

2L NSCLC anti G12D (early data):
PFS: 11 months
ORR: 52%
G3 AEs: 13%

(Now compare that to 10 months with Osimertinib in 2L NSCLC)…

This can’t be FDA approved soon enough.

@OncoAlert @TheGutOncLab